Primel, a has announced the results from a first-of-its-kind clinical trial at Lancashire Teaching Hospital Trust of its Primel Active Hand Shield (PAHS) technology.
In the trial, the UK-based provider of innovative infection prevention infrastructure found that PAHS demonstrated an average of 91% higher antimicrobial efficacy after 1 hour, compared to the current standard of care hand sanitiser at 15 minutes.
Primel states that this is the world’s first-hand hygiene product that has both a broad spectrum of antimicrobial activity and long-lasting (residual) efficacy, providing much improved protection for patients.
Use of this innovative product will improve patient safety, addressing the current challenges of hand hygiene compliance by healthcare workers, and reduce the cost and burden of healthcare associated infections.
In the trial, PAHS demonstrated an average of 91% higher antimicrobial efficacy after 1 hour, compared to the current standard of care hand sanitiser at 15 minute
These efficacy results include the first broad-spectrum efficacy with sustained protection, that is effective against pathogens such as MRSA, Clostridium difficile, and norovirus.
This highlights the evolution of Primel’s infection prevention solution and provides an opportunity to review national and international health policies for safer hand hygiene.
Consultant Microbiologist and Head of Research and Development in Microbiology at the Leeds Teaching Hospitals, Mark Wilcox, said: “With hospital-acquired infection rates such as Clostridium difficile currently increasing annually within UK hospitals, and the challenges of spreading antimicrobial resistance, new solutions are needed to cut infection risks in healthcare settings.
Wilcox said that the trial showed PAHS efficacy was superior to current alcohol sanitisers that are in widespread use.
“This novel hand hygiene product offers the chance to break the infection transmission cycle and, importantly, provide increased safety for patients, healthcare professionals, and visitors. Going forward, infection prevention guidelines need to consider this novel way of improving hand hygiene”.
These unrivalled efficacy results include the first broad-spectrum efficacy with sustained protection, that is effective against pathogens such as MRSA, Clostridium difficile, and norovirus
The Lancashire Teaching Hospital Trust’s trial results demonstrated that the application of PAHS provides users with superior protection against a broad spectrum of pathogens, including some of the most drug-resistant microbes, on immediate application and over a continuous period as well as showing less transfer of pathogens to surfaces, compared to a traditional hand sanitiser.
After immediate application, Primel Active Hand Shield was 98% effective and after 1 hour
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Building Better Healthcare.
Subscribe now Already a subscriber? Sign in here.